Brief: Repare Therapeutics To Present Data From Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy In Multiple Advanced Solid Tumors Harboring ATM Loss-Of-Function At Esmo Congress 2024
13/09/2024 12:32
Sept 13 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS TO PRESENT DATA FROM PHASE 1/2 TRESR
CLINICAL TRIAL EVALUATING CAMONSERTIB MONOTHERAPY IN MULTIPLE
ADVANCED SOLID TUMORS HARBORING ATM LOSS-OF-FUNCTION AT ESMO
CONGRESS 2024
Source text for Eikon: ID:nBw1qmsJ6a
Further company coverage: RPTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln